GENERAL COMMENTS
Reviewer: Dr Birkneh Tilahun Tadesse Title: Incidence and risk factors of first line antiretroviral treatment failure among Human Immunodeficiency Virus infected children in Amhara Regional State, Ethiopia: Retrospective Cohort study Abstract: Methods: Your objective is to identify risk factors -would have been better if you employed a case-control design. In your case the controls are assigned at the end of the retrospective follow up and not purposively assigned to match the cases. The statistics also didn't consider the design. Results: Even though clinical evidences of treatment failure could be easily missed, usually children do not develop isolated clinical or immunologic treatment failure. If they fail immunologically, they would also have opportunistic infections defining clinical treatment failure.
Taking about opportunistic infections as a whole might not give much clinical sense. The authors would rather specify which OIs are related with higher risk of treatment failure.
Conclusion: With the mean age of the children being 6.4 years, I don't think this is logical. The authors might need to see it in subgroups. Disclosure is considered important after the age of 8 years.
What is viral monitor? What do you mean by early initiation? Now the national policy is "test and treat". Are you trying to recommend better testing policies?
Strength and Limitations:
The retrospective nature of the data is the main limitation and that should be spelled out clearly.
The assertion that clinical and immunologic criteria overestimate treatment failure is not true. You should first look though the literature before making such conclusions. They are actually known for underestimating virologic treatment failure. There are a lot of publications out there which report on the predictive capacity of clinical and immunologic criteria.
Background:
Generally: The background part lacks clarity with incomplete sentences, figures without references, etc. Moreover, the language is very poor. The national and regional policies regarding treatment of HIV infected children was not described in the background part.
Specific points: -Page 3, Line 4-6 needs a reference and should be recent; Line 18: sentence looks incomplete and also needs citation; Line 43-46: talks about studies but no citation. -Page 4: Line 6-11: please fact check Methods:
The "Study participants" part isn't clear…please re-word Sample size calculation based on the aHR powers your study to elicit associated factors with treatment failure. What about for the incidence? Study design isn't appropriate (risk factors can't be studied by a retrospective cohort study).
How was the simple random sampling done? Authors should be more specific. Example: recording all the MRNs and then using a lottery method (computer generated)... The authors should discuss the national guidelines for diagnosing immunologic and clinical treatment failure. They should also be referenced.
Much of the statistical analysis and data handling part is too technical and redundant. You just need to indicate how the data were analyzed and the statistics briefly in a way that is relevant to display your results.
Results:
Generally, the results section is poorly structured with language problems. More importantly, as the study reports on epidemiologic parameters of treatment failure in children (like incidence), the following main paints are lacking: -How many patients were screened? -How many were included? -How many were excluded and why? -What was the treatment failure status of those patients who were excluded? -How many were excluded because of incomplete recording?
There looks a mix up between results and methods. Definitions should generally be in the M&M not in the results. What is written under this section has very little clinical meaning and rather focuses on the statistical concepts. Statistical methods and justification for use can be described in the M & M (in a way that can be understood by most science readers), but not here and there.
Discussion:
The discussion part is also weak. It focuses on comparing numbers between studies other than explaining what the results of the current study mean in the context of local guidelines and other studies in the region. There is a lot of repetition of the results section. Limitations are not explicitly described and a few of the sentences are incorrect.
For example: the finding that duration on ART protects form treatment failure is counter-intuitive. The authors have not tried to explain what it means.
VERSION 1 -AUTHOR RESPONSE
Author's Point-by-Point Response to the Reviewer's and Editors Manuscript ID: bmjopen-2017-019181 Dear Editor, We would like to appreciate your time and concerns in improving the quality of the manuscript. Please find attached the revised manuscript and point by point responses to the comments of the referees. All comments of the referees are well taken and modifications have made based on the referees' comments. We thank the referees for their valuable comments which substantially improved the manuscript.
Respectfully, Malede Mequanent **N.B:-Please note that the responses to each question are started with bullets. #1, Responses for Editorial Requirements: Please work to improve the quality of the English throughout your manuscript. We encourage you to ask a native English speaking colleague to assist you.
• Comment accepted and the language is edited by language professional Please add a description of the Generalisability of the results to the discussion section, as per the requirements of the STROBE checklist. Generalisability describes the extent to which research findings can be applied to settings other than that in which they were originally tested.
• In Ethiopia HIV/AIDS care and treatment carried out based on a guideline so-called "National Guidelines for Comprehensive HIV Prevention, Care and Treatment" throughout the country. This study was carried out in Amhara region hospitals which accommodate service based on the above guideline for patients come in every corner of the region specifically and Nation generally. So this study can be generalized to the larger population since we have taken adequate sample size and strong study design. Therefore, these findings may be generalisable to treatment -experienced patients. Since our patients participated in large multicentre within the region and country. As well as their experience may not differ from that of patients accessing treatment in a remaining community based setting due to all hospitals follow the same guidelines and supports. In the future studies should be conducted to evaluate the best approaches to use HIV-RNA monitoring (see page [16] [17] #2, Response to Comments from Reviewer # 1 Write-up and Grammar: the manuscript is well written and the chronological order of concepts is kept well. There is a need to undertake further grammatical corrections such as "….of follow-up of up….." under the strength and limitations section; capitalization of the first letter of words; …."data was"…elsewhere in the document; "…About 90% New HIV…"..
• Comment accepted and the language is edited by the language professional. Background: the statements shall be organized keeping coherence of ideas. For example, the second and third lines of paragraph 2 deal with incidence of HIV infection while sentence 1 talks about ART, it is advisable to take these up with paragraph 1. It is good to present the validity of the three measurements of treatment failure as this was presented as limitation of the study.
• Comment accepted and the corrected section is presented (see page 3, line paragraph 1 & 2)
• The World Health Organization guideline recommend three criteria to determine treatment failure; Virological, clinical and immunological. The best criterion is virological, however due to cost implication the clinical and immunological have been used in resource limited settings as recommended by WHO. The validities of all the tests is assessed (see reference 8) Methods
Design: The document presented a retrospective follow-up study. The title displayed a retrospective cohort. Through these two are similar, researchers are advised to write one of the two preferably retrospective follow-up studies.
• Comment accepted and correction has mad accordingly (see the title). Study participants: the inclusion criterion "….and available their required information…" is unclear. Authors can present the respective characters that must be available for the child to be eligible.
• The baselines characteristics like age, CD4 count and had at least one visit after initiated of ART were considered as criteria (see page 5). Sample size and sampling technique: the sample size calculation used diarrhoea as the risk factor. However, this OI could be in itself an index for failure, meaning it is a component of outcome itself (as the definition presents). Authors may elaborate why they used this variable.
• Time to treatment failure is the outcome of interest in our study. From previous similar study, we found chronic diarrhoea as a significant determinant factor. Thus, we used this factor to get sufficient sample size (detail of the method can be found in reference 20). The last sentence "…The sample size was proportional allocated to each randomly selected hospital in order to obtain the best precision indicator of the event…" seems confusing as proportional allocation ensures that all hospitals, and hence locations, in the region are fairly represented BUT precision indicator is not clear.
• Comment accepted and the manuscript is revised accordingly (see page 5, second paragraph) Data collection: the definition of immunologic failure shall be written as it appears in the national guideline, rather than referring to it.
• Based on the national guideline, we have included the definition as follows. Immunologic failure declare when a child younger than 5 years should have persistent CD4 levels below 200 cells/mm3 or <10% and a child Older than 5 years should have persistent CD4 levels below 100 cells/mm3 (page 6.) Data analysis: the model testing statements seem to be repeated; as in the last two sentences.
• Comment accepted and the manuscript is revised accordingly (see page 7). Results Risk factors of treatment failure: Has adherence to treatment been measured precisely? As treatment duration increases, the level of adherence to treatment may fall down and leads to treatment failure. So researchers would explain on the measurement of adherence.
• Indeed, measuring adherence is not simple. However, we used the national and WHO ART guidelines to measure.
• Adherence can be assessed at each visit through ARV pill count or Pharmacy records and Missed or late clinic visits in resource-poor countries. In Ethiopia at all HIV clinic visits, the Healthcare provider assesses adherence to ART by pill counts at visit and records appropriately as "GOOD", "FAIR" or "POOR" adherence on the HIV care/ART card. Good adherence refers to ≥95 % adherence; fair refers to 80-95 % where poor adherence is less than 80 %. Therefore, we used this definition of adherence and included in the manuscript (see page 6). Discussion: again, the measurement of adherence in children remained difficult and be reflected in the limitations. On paragraph 2, the lower incidence of treatment failure in this study as compared to other findings was attributed to the improvements of HIV care over time, but again staying longer in treatment course has a negative effect on treatment failure in your study participants. These two i deas contradict and need explanation.
• Comment accepted and the manuscript is reviewed accordingly.
• Thank you for your insight. Indeed the two ideas seem to contradict. However, in the ART setting, countries encourage earlier HIV diagnosis and earlier antiretroviral treatment and promote the use of less toxic regimens and more strategic laboratory monitoring. In addition, monitoring is improving from time to time both by the health professional and caregivers. Still staying longer could have negative effect on treatment failure. Conclusions: Researchers recommended early initiation of treatment but are unclear why this would be relevant on top of many characteristics considered as risk factors such as duration of therapy.
Moreover, the importance of initiation at earlier WHO stages of disease was not shown in the multivariable analysis.
• We revised the manuscript based on your comment (see page17 and Abstract) Bibliography: there are areas that need editing. Page numbers, list of authors, name of journals….starting from ref #1
• Comment accepted and revision has been made in the final manuscript #3, Response to Comments from Reviewer # 2 Abstract: Methods: Your objective is to identify risk factors-would have been better if you employed a case control design. In your case the controls are assigned at the end of the retrospective follow up and not purposively assigned to match the cases. The statistics also didn't consider the design.
• Indeed it could be possible to use case control design had our objective was only to identify risk factors. However, the objectives of this study were to determine both the incidence of treatment failure and identify its risk factors. Thus we prefer retrospective follow-up study with chart review among HIVinfected children receiving medical care at the major HIV Care Clinic in the region.
• We calculated times to treatment failure and person-years, and a Weibull Cox-regression model was used to compare the risk of Patient characteristics. Results: Even though clinical evidences of treatment failure could be easily missed, usually children do not develop isolated clinical or immunologic treatment failure. If they fail immunologically, they would also have opportunistic infections defining clinical treatment failure. Taking about opportunistic infections as a whole might not give much clinical sense. The authors would rather specify which OIs are related with higher risk of treatment failure.
• We agree with your suggestion. But we included additional figures in result section. From preliminary analysis, we used each OI as function of treatment failure, but none of them showed significant effects. In the contrary, the overall OIs status (having at least one common OI) showed statistical effect in both bivariable and multivariable analysis. That is why we prefer to include in this manner and this will help to care OIs and have to get attention of health care providers and policymakers (see page 8) Conclusion: With the mean age of the children being 6.4 years, I don't think this is logical. The authors might need to see it in sub-groups. Disclosure is considered important after the age of 8 years. What is viral monitor? What do you mean by early initiation? Now the national policy is "test and treat". Are you trying to recommend better testing policies?
• We believe mean is a logical measure overall statistics as many retrospective follow-up studies supported. The detailed Subgroup analysis is given in table 1. We enrolled all children, due to high access to PMTCT services in Ethiopia. The national ART guideline indicates that Viral load test should be done after 6 months of initiating ART and every 12 months then after in order to detect treatment failure proactively. Viral load testing should be used apart from the routine testing whenever there is clinical or immunologic suspicion of treatment failure. However, Viral loads were not used to confirm treatment failure in all of the cases included in the reported due to lack of viral load monitoring.
• Early initiation means monitor Clinical/ Immunological Suspicion of treatment failure. The healthcare provider should detect treatment failure, which is very important for optimal management of HIVinfected patients receiving ART. Then Do Viral load test to confirm and Switch to 2nd line regimen whenever failed the 1st line regimen. In addition to routine clinical and laboratory assessment, It is recommended that the health care provider, government and research should Consider adequate viral load test and drug resistance test. This might be highlighted the effectiveness of first -line regimens (see page 17) Strength and Limitations: The retrospective nature of the data is the main limitation and that should be speled out clearly. The assertion that clinical and immunologic criteria overestimate treatment failure is not true. You should first look though the literature before making such conclusions. They are actually known for underestimating virologic treatment failure. There are a lot of publications out there which report on the predictive capacity of clinical and immunologic criteria.
• Comment accepted and revision has been made in the final manuscript • Infact it is underestimated virologic treatment failure. We explained as underestimate in the discussion, but unfortunately, there were misspelt with this heading. It was correctly written in the discussion part. So we acknowledged your insight. After rigorous literature reviewed on the available data, we included validity of the three measurements of treatment failure in the background section. Background: Generally: The background part lacks clarity with incomplete sentences, figures without references, etc. Moreover, the language is very poor. The national and regional policies regarding treatment of HIV infected children were not described in the background part. Specific points: -Page 3, Line 4-6 needs a reference and should be recent; Line 18: sentence looks inc omplete and also needs citation; Line 43-46: talks about studies but no citation. -Page 4: Line 6-11: please fact check • Comment accepted and revision has been made in the final manuscript. The language is also edited by language professional. Methods: The "Study participants" part isn't clear…please re-word Sample size calculation based on the HR powers your study to elicit associated factors with treatment failure. What about for the incidence? Study design isn't appropriate (risk factors can't be studied by a retrospective cohort study). How was the simple random sampling done? Authors should be more specific. Example: recording all the MRNs and then using a lottery method (computer generated)... The authors should discuss the national guidelines for diagnosing immunologic and clinical treatment failure. They should also be referenced. Much of the statistical analysis and data handling part is too technical and redundant. You just need to indicate how the data were analyzed and the statistics briefly in a way that is relevant to display your results.
• Comment accepted and revision has been made in the final manuscript Results: Generally, the results section is poorly structured with language problems. More importantly, as the study reports on epidemiologic parameters of treatment failure in children (like incidence), the following main paints are lacking: -How many patients were screened? -How many were included? -How many were excluded and why? -What was the treatment failure status of those patients who were excluded? -How many were excluded because of incomplete recording? There looks a mix up between results and methods. Definitions should generally be in the M&M not in the results. "About one fourth of children 8 (25%) were received only Nevirapine (NVP) ARV during PMTCT…" which children? 8% of what? When was confirmation of treatment failure made foremost children? What was the delay between? Developments of treatment failure and its diagnosis? Page 11, Predictors of Treatment Failure: What is written under this section has very little clinical meaning and rather focuses on the statistical concepts. Statistical methods and justification for use can be described in the M & M (in a way that can be understood by most science readers), but not here and there.
• Comment accepted and revision has been made in the final manuscript • We really appreciate your concern. As we included additional results and explanations in result section. To mention some of them, Treatment failure is confirmed with Virological failure (Plasma viral 
